Cargando…

The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection

BACKGROUND AND OBJECTIVE: Hepatocellular carcinoma (HCC) often invades the portal vein and its branches to form portal vein tumor thrombus (PVTT), and it rarely spreads into the bile ducts to cause bile duct tumor thrombus (BDTT). However, the clinical prognosis of patients with the two types of tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xin, Zhu, Ying, Zhao, Xia, Li, Jian-hua, Xu, Da, Jia, Hu-Liang, Zhang, Ju-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700003/
https://www.ncbi.nlm.nih.gov/pubmed/33262656
http://dx.doi.org/10.2147/CMAR.S278777
_version_ 1783616178843811840
author Yang, Xin
Zhu, Ying
Zhao, Xia
Li, Jian-hua
Xu, Da
Jia, Hu-Liang
Zhang, Ju-bo
author_facet Yang, Xin
Zhu, Ying
Zhao, Xia
Li, Jian-hua
Xu, Da
Jia, Hu-Liang
Zhang, Ju-bo
author_sort Yang, Xin
collection PubMed
description BACKGROUND AND OBJECTIVE: Hepatocellular carcinoma (HCC) often invades the portal vein and its branches to form portal vein tumor thrombus (PVTT), and it rarely spreads into the bile ducts to cause bile duct tumor thrombus (BDTT). However, the clinical prognosis of patients with the two types of tumor thrombus is different. In this manuscript, we plan to compare the prognosis of HCC with PVTT and BDTT for further clinical treatment. PATIENTS AND METHODS: A total of 60 patients including 48 HCC cases with PVTT and 12 HCC cases with BDTT were enrolled in the study. The medical records were collected from participants. The follow-up was performed in 3 years post-hepatectomy. Statistical analysis was performed to explore the relationship between tumor thrombus with clinicopathological characteristics, to determine the significant preoperative factors influencing overall survival (OS) and time to recurrence (TTR), and to establish the survival and recurrent curves. RESULTS: HCC with BDTT or PVTT often combined with viral hepatitis B, accompanied by varying degrees of cirrhosis, and high AFP level (68.3%), complete tumor capsule (76.7%), and larger tumor size (85.0%). Furtherly, patients with HCC and BDTT tended to have higher total bilirubin (TB) and more possibility of lymph node metastases. The multivariate Cox hazard analyses also revealed that both tumor size and tumor thrombus could be taken as independent prognostic indicators of HCC patients. Survival curves showed that the 1-, 2- and 3-year OS or DFS rates of HCC patients with BDTT were significantly lower than those of HCC patients with PVTT, respectively. CONCLUSION: Tumor thrombus is an independent risk factor for poor survival and high recurrence in HCC. HCC patients with BDTT had shorter overall survival and higher tumor recurrence rate compared to HCC patients with PVTT.
format Online
Article
Text
id pubmed-7700003
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77000032020-11-30 The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection Yang, Xin Zhu, Ying Zhao, Xia Li, Jian-hua Xu, Da Jia, Hu-Liang Zhang, Ju-bo Cancer Manag Res Original Research BACKGROUND AND OBJECTIVE: Hepatocellular carcinoma (HCC) often invades the portal vein and its branches to form portal vein tumor thrombus (PVTT), and it rarely spreads into the bile ducts to cause bile duct tumor thrombus (BDTT). However, the clinical prognosis of patients with the two types of tumor thrombus is different. In this manuscript, we plan to compare the prognosis of HCC with PVTT and BDTT for further clinical treatment. PATIENTS AND METHODS: A total of 60 patients including 48 HCC cases with PVTT and 12 HCC cases with BDTT were enrolled in the study. The medical records were collected from participants. The follow-up was performed in 3 years post-hepatectomy. Statistical analysis was performed to explore the relationship between tumor thrombus with clinicopathological characteristics, to determine the significant preoperative factors influencing overall survival (OS) and time to recurrence (TTR), and to establish the survival and recurrent curves. RESULTS: HCC with BDTT or PVTT often combined with viral hepatitis B, accompanied by varying degrees of cirrhosis, and high AFP level (68.3%), complete tumor capsule (76.7%), and larger tumor size (85.0%). Furtherly, patients with HCC and BDTT tended to have higher total bilirubin (TB) and more possibility of lymph node metastases. The multivariate Cox hazard analyses also revealed that both tumor size and tumor thrombus could be taken as independent prognostic indicators of HCC patients. Survival curves showed that the 1-, 2- and 3-year OS or DFS rates of HCC patients with BDTT were significantly lower than those of HCC patients with PVTT, respectively. CONCLUSION: Tumor thrombus is an independent risk factor for poor survival and high recurrence in HCC. HCC patients with BDTT had shorter overall survival and higher tumor recurrence rate compared to HCC patients with PVTT. Dove 2020-11-24 /pmc/articles/PMC7700003/ /pubmed/33262656 http://dx.doi.org/10.2147/CMAR.S278777 Text en © 2020 Yang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Xin
Zhu, Ying
Zhao, Xia
Li, Jian-hua
Xu, Da
Jia, Hu-Liang
Zhang, Ju-bo
The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection
title The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection
title_full The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection
title_fullStr The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection
title_full_unstemmed The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection
title_short The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection
title_sort prognostic comparison between hepatocellular carcinoma with portal vein tumor thrombus and bile duct cancer thrombus after liver resection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700003/
https://www.ncbi.nlm.nih.gov/pubmed/33262656
http://dx.doi.org/10.2147/CMAR.S278777
work_keys_str_mv AT yangxin theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT zhuying theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT zhaoxia theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT lijianhua theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT xuda theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT jiahuliang theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT zhangjubo theprognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT yangxin prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT zhuying prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT zhaoxia prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT lijianhua prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT xuda prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT jiahuliang prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection
AT zhangjubo prognosticcomparisonbetweenhepatocellularcarcinomawithportalveintumorthrombusandbileductcancerthrombusafterliverresection